A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer

确定用于治疗儿科和 AYA 高风险肉瘤、肾癌和肝癌的新药的测试计划

基本信息

项目摘要

ABSTRACT Cancer in children is rare with approximately 15,700 new cases diagnosed annually in children 21 years or younger in the U.S. Through use of multimodality therapy (surgery, radiation therapy, and aggressive chemotherapy), 70% of patients will be `cured' of their disease, and 5-year Event-Free Survival (EFS) exceeds 80%. Consequently, the number of patients that can be enrolled in phase I/II clinical trials is small, and most patients will have been extensively treated, hence drug/radiation resistant. Thus, preclinical studies that accurately translate into effective clinical therapy are an essential component of pediatric drug development. Our group has contributed to studies in the PPTP/C that have led to clinical studies through Children's Oncology Group (COG). Of importance, we have developed and characterized over 330 Patient Derived Xenografts (PDX), developed from tumors both at diagnosis and relapse, that can be used to facilitate pediatric drug development as directed by FDA under the Research to Accelerate Cures and Equity for Children Act (RACE for Children Act). Based on our studies, both in and outside the PPTC, we propose to use PDX/CDX models of sarcoma, kidney cancer, and hepatoblastoma derived from high-risk patients to identify novel agents and combinations, and to test at least 8-10 agents per year, for which we have expertise. We will explore specific hypotheses to integrate molecular-targeted agents with conventional chemo-radiation treatment, advanced drug delivery systems (antibody-drug conjugates, nanoparticles), and the use of Single Mouse Testing (SMT) as the primary screening approach. In collaborative studies, we will evaluate a new humanized mouse model where testing of immuno-oncology agents is a priority to treat these PDX models. One of the objective limitations of PPTP/C testing was that relatively few tumor models representing a specific disease (n=3-8/disease) could be used within the resource constraints, a number clearly insufficient to recapitulate the genetic/epigenetic heterogeneity of each clinical disease. Our retrospective analysis of PPTP data, and recent prospective testing in the PPTC, shows that a single mouse/tumor line gives essentially similar data to conventional testing' (using 10 mice/group for each tumor line). The advantage of the SMT design is that it allows for incorporation of up to 20-fold more models, more accurately representing the genetic/epigenetic diversity of each pediatric cancer within the same resource constraints. The proposed studies will adopt SMT as the primary screening approach to identify agents that have biologically meaningful activity (i.e. large antitumor effects) and identify tumors that are `exceptional responders' for validation. The SMT approach, when linked to the molecular characterization of PDX models, potentially increases the power to identify biomarkers associated with response. Using SMT we can essentially conduct preclinical phase II trials and simulate the likely clinical response rate more accurately for a given disease. As part of the Ped-In Vivo-TP, we aim to develop highly effective, less toxic therapies for high-risk cancers that afflict children and adolescents/young adults (AYA).
抽象的 儿童癌症很少见,每年大约有 15,700 例 21 岁或 21 岁儿童新诊断病例 在美国,通过使用多学科治疗(手术、放射治疗和积极的治疗),年轻化 化疗),70% 的患者的疾病将被“治愈”,并且 5 年无事件生存期 (EFS) 超过 80%。因此,能够参加I/II期临床试验的患者数量很少,而且大多数 患者将接受广泛治疗,因此具有药物/放射抵抗力。因此,临床前研究表明 准确转化为有效的临床治疗是儿科药物开发的重要组成部分。我们的 小组对 PPTP/C 的研究做出了贡献,这些研究导致了儿童肿瘤学的临床研究 组(COG)。重要的是,我们已经开发并表征了超过 330 个患者来源的异种移植物 (PDX), 在诊断和复发时由肿瘤发展而来,可用于促进儿科药物开发 按照 FDA 根据《加速治疗和儿童公平研究法案》(RACE for Children 行为)。根据我们在 PPTC 内外的研究,我们建议使用肉瘤的 PDX/CDX 模型, 来自高危患者的肾癌和肝母细胞瘤,以确定新的药物和组合, 每年测试至少 8-10 个代理,我们对此有专业知识。我们将探讨具体的假设 将分子靶向药物与传统放化疗、先进药物输送相结合 系统(抗体药物偶联物、纳米颗粒),以及使用单鼠测试(SMT)作为主要方法 筛选方法。在合作研究中,我们将评估一种新的人源化小鼠模型,其中测试 免疫肿瘤药物是治疗这些 PDX 模型的首要任务。 PPTP/C的客观局限性之一 测试表明,代表特定疾病(n=3-8/疾病)的肿瘤模型相对较少 资源限制,这个数字显然不足以概括遗传/表观遗传异质性 各临床疾病。我们对 PPTP 数据的回顾性分析以及最近在 PPTC 中的前瞻性测试, 表明单个小鼠/肿瘤系提供的数据与传统测试基本相似”(使用 10 只小鼠/组) 对于每个肿瘤系)。 SMT 设计的优势在于它允许并入多达 20 倍的器件 模型,更准确地代表同一区域内每种儿科癌症的遗传/表观遗传多样性 资源限制。拟议的研究将采用 SMT 作为识别药物的主要筛选方法 具有生物学意义的活性(即大的抗肿瘤作用)并识别“特殊”的肿瘤 响应者进行验证。当 SMT 方法与 PDX 模型的分子表征联系起来时, 可能会增加识别与反应相关的生物标志物的能力。使用 SMT,我们基本上可以 进行临床前 II 期试验并更准确地模拟给定情况下可能的临床反应率 疾病。作为 Ped-In Vivo-TP 的一部分,我们的目标是为高危患者开发高效、毒性较小的疗法 困扰儿童和青少年/年轻人的癌症 (AYA)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PETER J HOUGHTON其他文献

PETER J HOUGHTON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PETER J HOUGHTON', 18)}}的其他基金

A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer
确定用于治疗儿科和 AYA 高风险肉瘤、肾癌和肝癌的新药的测试计划
  • 批准号:
    10461141
  • 财政年份:
    2021
  • 资助金额:
    $ 60.07万
  • 项目类别:
A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer
确定用于治疗儿科和 AYA 高风险肉瘤、肾癌和肝癌的新药的测试计划
  • 批准号:
    10652439
  • 财政年份:
    2021
  • 资助金额:
    $ 60.07万
  • 项目类别:
Pediatric Preclinical Testing Consortium: Research Programs non-CNS
儿科临床前测试联盟:非中枢神经系统研究项目
  • 批准号:
    10293155
  • 财政年份:
    2020
  • 资助金额:
    $ 60.07万
  • 项目类别:
Pediatric Preclinical Testing Consortium: Research Programs non-CNS
儿科临床前测试联盟:非中枢神经系统研究项目
  • 批准号:
    10076139
  • 财政年份:
    2020
  • 资助金额:
    $ 60.07万
  • 项目类别:
Pediatric Preclinical Testing Consortium: Research Programs Non-CNS (U01)
儿科临床前测试联盟:非 CNS 研究项目 (U01)
  • 批准号:
    8968480
  • 财政年份:
    2015
  • 资助金额:
    $ 60.07万
  • 项目类别:
Pediatric Preclinical Testing Consortium: Research Programs Non-CNS (U01)
儿科临床前测试联盟:非 CNS 研究项目 (U01)
  • 批准号:
    9315791
  • 财政年份:
    2015
  • 资助金额:
    $ 60.07万
  • 项目类别:
INSULIN-LIKE GROWTH FACTOR SIGNALING AS A THERAPEUTIC TARGET IN CHILDHOOD SARCOM
胰岛素样生长因子信号作为儿童 SARCOM 的治疗靶点
  • 批准号:
    8516642
  • 财政年份:
    2013
  • 资助金额:
    $ 60.07万
  • 项目类别:
XENOGRAFT AND CELL LINE CORE
异种移植物和细胞系核心
  • 批准号:
    8516644
  • 财政年份:
    2013
  • 资助金额:
    $ 60.07万
  • 项目类别:
Therapeutic Exploitation of Mutant BRAF for Astrocytoma
突变 BRAF 对星形细胞瘤的治疗利用
  • 批准号:
    8584135
  • 财政年份:
    2013
  • 资助金额:
    $ 60.07万
  • 项目类别:
Studies of Childhood Sarcomas
儿童肉瘤的研究
  • 批准号:
    8476016
  • 财政年份:
    2013
  • 资助金额:
    $ 60.07万
  • 项目类别:

相似海外基金

How novices write code: discovering best practices and how they can be adopted
新手如何编写代码:发现最佳实践以及如何采用它们
  • 批准号:
    2315783
  • 财政年份:
    2023
  • 资助金额:
    $ 60.07万
  • 项目类别:
    Standard Grant
One or Several Mothers: The Adopted Child as Critical and Clinical Subject
一位或多位母亲:收养的孩子作为关键和临床对象
  • 批准号:
    2719534
  • 财政年份:
    2022
  • 资助金额:
    $ 60.07万
  • 项目类别:
    Studentship
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
  • 批准号:
    2633211
  • 财政年份:
    2020
  • 资助金额:
    $ 60.07万
  • 项目类别:
    Studentship
A material investigation of the ceramic shards excavated from the Omuro Ninsei kiln site: Production techniques adopted by Nonomura Ninsei.
对大室仁清窑遗址出土的陶瓷碎片进行材质调查:野野村仁清采用的生产技术。
  • 批准号:
    20K01113
  • 财政年份:
    2020
  • 资助金额:
    $ 60.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
  • 批准号:
    2436895
  • 财政年份:
    2020
  • 资助金额:
    $ 60.07万
  • 项目类别:
    Studentship
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
  • 批准号:
    2633207
  • 财政年份:
    2020
  • 资助金额:
    $ 60.07万
  • 项目类别:
    Studentship
The limits of development: State structural policy, comparing systems adopted in two European mountain regions (1945-1989)
发展的限制:国家结构政策,比较欧洲两个山区采用的制度(1945-1989)
  • 批准号:
    426559561
  • 财政年份:
    2019
  • 资助金额:
    $ 60.07万
  • 项目类别:
    Research Grants
Securing a Sense of Safety for Adopted Children in Middle Childhood
确保被收养儿童的中期安全感
  • 批准号:
    2236701
  • 财政年份:
    2019
  • 资助金额:
    $ 60.07万
  • 项目类别:
    Studentship
A Study on Mutual Funds Adopted for Individual Defined Contribution Pension Plans
个人设定缴存养老金计划采用共同基金的研究
  • 批准号:
    19K01745
  • 财政年份:
    2019
  • 资助金额:
    $ 60.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Structural and functional analyses of a bacterial protein translocation domain that has adopted diverse pathogenic effector functions within host cells
对宿主细胞内采用多种致病效应功能的细菌蛋白易位结构域进行结构和功能分析
  • 批准号:
    415543446
  • 财政年份:
    2019
  • 资助金额:
    $ 60.07万
  • 项目类别:
    Research Fellowships
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了